Profound Medical Corp. develops and markets interventional MRI medical devices for incision-free tissue ablation. Its recurring news centers on TULSA-PRO® and the TULSA Procedure™, which use real-time MRI guidance, robotically controlled transurethral ultrasound and temperature feedback to ablate prostate tissue in prostate cancer and benign prostatic hyperplasia.
Company updates also cover Sonalleve®, an MRI-guided therapy used for pain palliation of bone metastases, desmoid tumors and osteoid osteoma, as well as gynecologic conditions including uterine fibroids and adenomyosis. Recurring developments include financial results, revenue guidance, payer coverage, CAPTAIN post-market clinical data, scientific-meeting presentations, treatment-site adoption milestones and investor conference updates.
Profound Medical (NASDAQ:PROF) reported record Q3 2025 revenue of $5.3M, up 87% YoY, driven by $4.1M recurring non-capital revenue and $1.2M capital equipment sales. Gross margin expanded 1,119 bps to 74.3% on manufacturing efficiency. Installed base reached 70 systems with a qualified pipeline of 93 new systems; the company expects at least 75 installs by year-end. Q3 net loss improved to $8.0M ($0.26/share) from $9.4M a year ago. Cash was approximately $24.8M as of September 30, 2025. The company announced new distribution agreements and clinical program milestones to support adoption.
Profound Medical (NASDAQ:PROF) announced an exclusive distribution and supply agreement with Getz Healthcare to commercialize the TULSA-PRO system in Australia and New Zealand, dated November 12, 2025. TULSA-PRO is an AI-powered, MRI-guided, robotically controlled system for prostate ablation that enables real-time MRI thermography and autonomous temperature control.
The partnership aims to expand access to incision-free prostate therapy in Australasia while Profound continues direct sales in North America and seeks further APAC distribution opportunities with Getz Healthcare.
Profound Medical (NASDAQ:PROF) announced an exclusive distribution and supply agreement with Al Faisaliah Medical Systems for its incision-free, MRI-guided TULSA-PRO and Sonalleve technologies in Saudi Arabia on Nov 11, 2025. All required import and sales regulatory approvals for Saudi Arabia are in place. TULSA-PRO has an installed base of 67 systems (Oct 2025) and >4,000 men treated; Sonalleve has 10 devices operational globally and >4,000 women treated for uterine conditions. The deal targets the Kingdom’s large healthcare market and leverages FMS’s regional distribution capabilities.
Profound Medical (NASDAQ:PROF) regained exclusive Canadian distribution rights for the TULSA-PRO system from Knight effective Nov 10, 2025, in exchange for a one-time payment of CDN$90,000 (US$64,000) and a 5% royalty on Canadian Net Sales for 15 years. Currently only Sunnybrook Health Sciences Centre in Toronto offers the TULSA Procedure and has performed >100 procedures. Profound plans to deploy its North American direct sales team, pursue additional Canadian sites through a concierge model, and use upcoming CAPTAIN trial results (readouts starting 2026) to support provincial coverage applications.
Profound Medical (NASDAQ:PROF) announced real-world data from the Busch Center marking its 500th TULSA Procedure on Oct 16, 2025. The center reported a mix of indications: ~50% primary prostate cancer, ~33% BPH, and remaining salvage cases.
Key outcomes include whole-gland ablations covering >90% of prostate in >75% of cases, treatment volumes up to 250 cc, >15% high-risk cancers treated, and a retrospective PSA fall from 6.7 to 0.9 ng/mL with 93% no residual disease. Reported functional outcomes: 100% pad-free continence and 82% preserved erectile function in the analyzed cohort.
Profound Medical (NASDAQ:PROF) will present an update at the Stifel 2025 Healthcare Conference on Tuesday, November 11, 2025 at 1:20 p.m. ET in New York City. Management's presentation will be broadcast live and later archived on the company's investor website under News & Events.
The company describes itself as a commercial-stage medical device maker of customizable, AI-powered, incision-free therapies for tissue ablation.
Profound Medical (NASDAQ:PROF) announced preliminary unaudited Q3 2025 revenue of $5.2M–$5.3M, representing 84%–87% YoY growth versus $2.8M in Q3 2024. Gross margin is expected to be ~72%, up from 64% a year ago. The company reported its TULSA-PRO installed base at 67, up from 60, and said it still expects to reach at least 75 systems by year-end.
These figures are preliminary and unaudited; full Q3 2025 results will be released after market close on November 13, 2025, followed by a conference call at 4:30 p.m. ET.
Profound Medical Corp. (NASDAQ:PROF) announced a groundbreaking partnership between Texas Prostate and Dallas Medical Center to launch a first-of-its-kind TULSA program. The collaboration expands Medicare patient access to the TULSA Procedure™, an advanced, AI-powered prostate treatment technology.
The program enables Texas Prostate to perform TULSA procedures at Dallas Medical Center's MRI suite, treating both prostate cancer and benign prostatic hyperplasia (BPH). This advancement follows Medicare's coverage approval in January 2025 for TULSA procedures across various healthcare settings.
The TULSA-PRO® system represents a significant innovation in prostate care, utilizing robotically-guided ultrasound within an MRI environment to precisely ablate targeted prostate tissue. The procedure offers key advantages including same-day discharge, no procedural blood loss, and reduced risk of complications like incontinence or erectile dysfunction.
Profound Medical (NASDAQ:PROF), a commercial-stage medical device company specializing in incision-free tissue ablation therapies, will participate in the Lake Street Capital Markets "BIG9" Conference on September 11, 2025 in New York City. The company's management will engage in one-on-one meetings with investors during the conference. No webcast will be available for this event due to its format.
Profound Medical (NASDAQ:PROF) reported Q2 2025 financial results, with revenue of $2.2 million, unchanged year-over-year, comprising $1.6 million from recurring revenue and $650,000 from capital equipment sales. The company's gross margin improved to 73% from 64% in the prior year.
TULSA-PRO® system showed strong operational metrics with 10% sequential growth in procedure volumes and a pipeline of 80 new systems in various sales stages. The company launched TULSA-AI® Volume Reduction Module for BPH treatment and appointed Leonard Wheeler as Global Ambassador. Despite some delayed capital sales, Profound maintains its guidance of 70-75% year-over-year revenue growth for 2025.